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ABSTRACT 
 Hepatocyte growth factor (HGF) is under development for treatment of renal 
failure. This study was designed to clarify changes in HGF pharmacokinetics in renal 
failure and to establish a pharmacokinetic model applicable to single and repeated doses. 
The plasma concentration profile in mice with glycerol-induced acute renal failure was 
similar to that in normal mice, indicating a minimal contribution of kidney to systemic 
clearance of HGF. Nevertheless, accumulation of FITC-labeled HGF in renal tubules in 
both cases suggests the occurrence of efficient endocytosis of HGF in kidney. A 
pharmacokinetic model including plasma and liver compartments was constructed, 
incorporating both high- and low-affinity receptors for association and subsequent 
endocytosis of HGF, because HGF is eliminated via specific receptor c-Met and 
heparin-like substance. The model well explained the plasma concentration profiles at all 
doses examined after bolus injection in animals and humans, and those during infusion in 
rodents. It includes externalization of receptors, which is negatively regulated by HGF, and 
can explain the gradual increase in trough concentration during repeated dosing in monkeys. 
Overall pharmacokinetic profiles of HGF are governed by at least two receptors and are 





Keywords: Pharmacokinetics/pharmacodynamics, Proteins, Receptors, Hepatic clearance, 
Elimination, Hepatocytes, Distribution 
 
INTRODUCTION 
Hepatocyte growth factor (HGF) was first identified as a potent mitogen for 
matured hepatocytes and is now recognized as a pleiotropic factor with a range of 
biological activities in epithelial and endothelial cells.1,2 Systemic administration of HGF 
has various beneficial effects in renal failure models in experimental animals. In a mouse 
model of obstructive nephropathy, for example, HGF attenuates the progression of 
interstitial fibrosis with a concomitant reduction in tubular apoptosis and an increase in 
tubular proliferation.3-5 In nephritic mice, HGF protects podocytes from nephron loss, 
leading to a reduction of proteinuria.6,7 In rats, HGF gene transfer reduces cyclosporin 
A-induced tubulointerstitial injury.8 Due to such promising biological activities and the 
limited availability of therapeutic agents for renal failure, there is great current interest in 
HGF as a potential treatment for renal failure.  
HGF has also been reported to prevent fulminant hepatic failure through 
antiapoptotic action,9 to ameliorate pulmonary emphysema,10 to reverse chronic vocal 
scarring11 and to promote therapeutic angiogenesis in a peripheral arterial disease model.12 
Recent phase I/II clinical studies in patients with some of those organ failures revealed no 
severe side effects of HGF treatment in humans.13,14 However, the multiple biological 
activities of HGF do raise the possibility that undesirable effects might occur after systemic 
administration without careful control of the dose regimen. Therefore, it is essential to 
understand the overall pharmacokinetics of HGF in humans. 
The various biological activities of HGF are thought to be primarily mediated by 
HGF receptor (c-Met protooncogene product).1,2 This receptor is also proposed to be 
involved in systemic clearance of HGF. For example, after down-regulation, i.e., reduction 
of the receptor density on the cell surface, induced by the injection of a relatively high dose 
of HGF, the total body clearance of 125I-HGF first decreased, but subsequently increased 
due to recruitment of c-Met/HGF receptor to the cell surface.15 A series of pharmacokinetic 
studies has clarified aspects of the pharmacokinetics of HGF in rats: (i) the liver is the 
major clearance organ for HGF;16-19 (ii) the pharmacokinetics of HGF is nonlinear due to 
the presence of two saturable elimination mechanisms;18,19 (iii) the high- and low-affinity 
elimination mechanisms have been identified as receptor-mediated endocytosis (RME) via 
c-Met/HGF receptor and endocytosis via cell-surface heparin-like substance, 
respectively.15-18 The molecular mechanism of the latter elimination pathway is still 
unknown, but this elimination may be mediated by heparan-sulfate proteoglycans, which 
are known to bind HGF.20,21 However, despite the pharmacokinetic information obtained in 
experimental animals and humans, no physiologically based pharmacokinetic model for 
HGF has yet been developed. In addition, repetitive injection of HGF is usually needed to 
obtain pharmacological effects in vivo in experimental animals3-9 and might be necessary in 
clinical application, but nevertheless, no data are available regarding the pharmacokinetic 
profile after repeated administration of HGF. Down-regulation of the HGF receptor/c-Met 
induced by HGF injection would affect systemic clearance after repeated doses.15 
Considering the complexity of the pharmacokinetic properties of HGF, it seems essential to 
construct a mechanism-based pharmacokinetic model in experimental animals in order to 
understand in detail the disposition of HGF in humans. 
Therefore, the purpose of the present study was to develop a pharmacokinetic 
model that can explain the plasma concentration profiles of HGF after a single dose and 
during constant infusion and repeated dosing, in order to evaluate possible species 
differences in the pharmacokinetics of HGF and to assist in the safe management of clinical 
trials. In particular, we focused on the following three points: (i) pharmacokinetic behavior 
of HGF in nonlinear dose condition; (ii) the effect of acute renal failure (ARF) on 
pharmacokinetics of HGF; (iii) the effect of repeated doses on the HGF pharmacokinetics, 
and possible down-regulation and subsequent recovery of the HGF receptor.
MATERIALS AND METHODS 
Materials 
Recombinant human HGF (5 amino acid-deleted type) was supplied by Kringle 
Pharma Inc. (Osaka, Japan). Glycerol and fluorescein-4-isocyanate (FITC) were purchased 
from Wako Pure Chemical Industries (Osaka, Japan). All other reagents were commercial 
products of reagent grade.  
 
Animals 
Male ICR mice (25-35 g weight) were purchased from Japan Charles River Inc. 
(Yokohama, Japan) and maintained with free access to food and water. This study was 
carried out in accordance with the Guide for the Care and Use of Laboratory Animals at the 
Takara-machi Campus of Kanazawa University. To construct the acute renal failure (ARF) 
model, glycerol dissolved in saline (50% v/v) was injected at 9 mL/kg into the hind leg of 
each mouse. At 24 and 48 hr later, blood urea nitrogen (BUN) and alanine transaminase 
activity (ALT) in plasma were determined using the corresponding assay kits (Wako Pure 
Chemical) according to the manufacturer’s instructions. 
 
Synthesis of FITC-HGF 
HGF (2 mg/mL) dissolved in 0.1 M sodium bicarbonate buffer (pH 9.0) was 
mixed with FITC (3 mg/mL) dissolved in DMSO and incubated at 4 oC for 8 hr, followed 
by further incubation for 2 hr after addition of 1 M NH4Cl. FITC-HGF was purified by gel 
filtration on a PD-10 column (Bio-rad, Hercules, CA) equilibrated with phosphate-buffered 
saline (PBS) containing 0.1% BSA, and stored at -80°C until use. 
 
Pharmacokinetic Studies 
Mice were fasted overnight with free access to water and anesthetized with 
diethylether during drug administration. HGF was diluted with 10 mM citrate buffer (pH 
7.0) containing 0.3 M NaCl, 0.05% polysorbate 80, 1% sucrose, 5 mg/mL L-alanine and 
0.2% BSA. HGF or cephalexin was then injected into the jugular vein, followed by blood 
sampling from the tail vein at 1, 5, 15, 30, 60, 240, 480, 720 and 1440 min for HGF and at 
1, 5, 15, 30, 60 min for cephalexin. For intravenous infusion, mice were anesthetized with 
pentobarbital, and HGF was infused via the jugular vein with a basic syringe pump 
(KDS-101, BrainScience Idea Co. Ltd., Osaka, Japan) at 2.7 µL /min without any loading 
dose. Blood was sampled from the jugular vein on the other side at 5, 10, 20 and 30 min. 
The blood was rapidly mixed with 1.25 mg /mL of EDTA•2Na solution (1 : 4) and 
centrifuged at 3,000 g for 15 min to obtain plasma, which was stored at -80°C until use. 
The HGF concentration in plasma was measured using an enzyme immunoassay kit for 
human HGF (Institute of Immunology Co. Ltd., Tokyo, Japan). According to the previous 
report22, this kit may almost exclusively detect intact HGF because the results obtained 
were well correlated to those obtained by western blot analysis and biological activity of 
HGF. For the quantification of cephalexin, the plasma samples were mixed with methanol. 
All the mixed solutions were centrifuged at 15,000 rpm for 10 min at 4 °C. After the 
centrifugation, the supernatants were diluted with mobile phase (at a volume ratio of 1:1) 
and again centrifuged. The supernatants were then subjected to HPLC analysis. The HPLC 
system consisted of a constant-flow pump (LC-10Avp, Shimadzu, Kyoto, Japan), a UV 
detector (SPD-M10Avp, Shimadzu), an automatic sample injector (SIL-10A, Shimadzu), 
and an integrator (CLASS-VP, Shimadzu). The reversed-phase column (Cosmosil 
5C18-AR-II, 4.6 x 150 mm; Nacalai Tesque) was maintained at 40˚C in a column oven 
(CTO-10Avp, Shimazu). The mobile phase was a mixture of 10 mM ammonium acetate 
and methanol (80:20), and the UV detector was set at 260 nm. The flow rate was 1.0 
mL/min. 
 
Tissue distribution of FITC-HGF 
FITC-HGF (0.1 mg/kg) was injected into the jugular vein. At 11 min later, 
heparin (5,000 units/kg) was further injected to dissociate cell-surface-bound HGF.17 At 15 
min after the FITC-HGF injection, mice were transcardially perfused with 
phosphate-buffered saline (PBS) containing heparin (50 units/mL) and then 4% 
paraformaldehyde dissolved in 0.1 mM phosphate buffer (pH 7.4). The kidney and liver 
were removed and successively immersed in 4% PFA, 10, 20 and 30% sucrose/PBS. The 
tissue was then frozen and sectioned with a cryostat, and the sections (20 µm) were 
mounted on glass slides. Fluorescence was detected with a confocal laser scanning 
fluorescence microscope (LSM 710, Carl Zeiss, Jena, Germany). 
 
Immunostaining of human HGF 
Frozen sections obtained as described above were used. For antigen activation, 
sections were heated to 92 ˚C in 20 mM Tris buffer (pH 9.0) for 15 min. Following 
successive pretreatment with 3% H2O2/PBS for 30 min, the sections were incubated with 
biotinylated anti-human HGF monoclonal antibody (Institute of Immunology Co. Ltd.) for 
2 hr at room temperature and then washed with PBS. The immunoreaction product was 
visualized by incubating the sections successively with VECTASTAIN Elite ABC Standard 
Kit (Vector Laboratories) for 30 min and Peroxidase Substrate Kit including 
3’,3’-diaminobenzidine tetrahydrochloride (ImmPACT DAB, Vector Laboratories). 
 
Construction of the pharmacokinetic model 
The model is shown in Figure S1 in Supporting Information, and includes plasma 
and liver compartments connected via the plasma flow rate (Qh). In the liver, HGF binds to 
two receptors, c-Met and heparin-like substance, followed by internalization of 
HGF-receptor complex with a rate constant kint and subsequent degradation (Fig. S1). 
Unbound receptor is also internalized with a rate constant kdeg and recruited to the 
cell-surface at a rate of Vsyn (Fig. S1). A mathematical model representing RME was 
principally established by Wiley and Cunningham.23 However, in the present study, 
considering that available information from clinical studies is limited, and only the plasma 
concentration profile can be fitted to the model, rapid equilibrium was assumed for the 
cell-surface binding of HGF to the receptors with a dissociation constant (Kd), to minimize 
the number of parameters. Mass-balance equations for plasma, liver and HGF receptors 
were, therefore, written as: 
Vp(dCp/dt) = - QCp + QCe + Vsyn,HGF            (1) 
dXliver/dt = QCp – QCe – kint,1(Ce Rtot,1 /(Kd,1 + Ce)) 
  – kint,2(Ce Rtot,2 /(Kd,2 + Ce)) - CLns Cp     
(2) 
 dRtot,1/dt = Vsyn,1 - kdeg,1 (Rtot,1 – (Ce Rtot,1 /(Kd,1 + Ce)))  
- kint,1 (Ce Rtot,1 /(Kd,1 + Ce))          (3) 
 dRtot,2/dt = Vsyn,2 - kdeg,2 (Rtot,2 – (Ce Rtot,2 /(Kd,2 + Ce)))  
- kint,2 (Ce Rtot,2 /(Kd,2 + Ce))          (4) 
where Cp and Vp are HGF concentration and distribution volume in the plasma 
compartment, respectively. Xliver and Rtot represent the amount of HGF and density of HGF 
receptor in the liver, respectively. As proposed in the previous report23, we assumed 
steady-state condition in the absence of HGF 
Vsyn – Rss kdeg = 0          (5) 
where Rss represents receptor density at the steady-state before the injection of HGF and 
was assumed to be the initial condition (receptor density at time zero) in pharmacokinetic 
analysis. According to Eq. (5), the kdeg can be written as Vsyn/Rss. The subscript numbers (1 
and 2) represent heparin-like substance and c-Met, respectively. CLns is non-saturable 
clearance and was considered only in monkeys (see Results). Vsyn,HGF represents the 
biosynthesis rate of endogenous HGF and was considered in monkeys, since enzyme 
immunoassay for human HGF also recognizes monkey HGF. Ce represents HGF 
concentration in the extracellular space and can be written as: 
 VeCe3 + (Rtot,1 + Rtot,2 + Kd,1Ve + Kd,2Ve - Xliver)Ce2 + (Kd,1Rtot,2 + Kd,2Rtot,1 +  
Kd,1Kd,2Ve - Kd,1Xliver - Kd,2Xliver)Ce – Kd,1Kd,2Xliver = 0     (6) 
where Ve represents the distribution volume in extracellular space (see Supporting 
Information for details of the derivation of these equations). 
 
Estimation of parameters 
All the pharmacokinetic parameters were estimated based on the mean values of 
plasma concentration data. Pharmacokinetic data used for estimation of parameters were 
partly obtained in the present study in mice, and partly taken from previous studies in 
rats18,19 and humans24, and preclinical studies in cynomolgus monkeys (Kringle Pharma 
Inc.). Qh was taken from the literature.25 Dissociation constants Kd,1 and Kd,2 were taken to 
be fixed at 1615 and 2.62 ng/mL, respectively (assuming that the molecular weight of HGF 
is 82,000), for the association of HGF with heparin-like substance and c-Met, 
respectively.26,27 In case of a single dose, Vsyn was assumed to be zero. During repeated 
dosing in monkeys, Vsyn was written follows, assuming negative feedback by HGF as 
reported for c-Met:28 
 Vsyn = Vsyn0 (1 – Ce / (IC50 + Ce))        (7) 
Here, the negative feedback was assumed to be mediated by the interaction of HGF with 
the corresponding receptor (c-Met and heparin-like substance), and therefore the IC50 was 
fixed as the Kd value for each receptor. Vsyn0 represents the zero-order rate constant. In 
rodents the other six parameters, kint,1, kint,2, Rtot,1, Rtot,1, Vp and Vp, were obtained by 
simultaneous nonlinear least-squares fitting of the model to the plasma concentration 
profiles at all doses examined after bolus injection and during infusion using the nonlinear 
regression analysis program Napp (Ver 2.0.1 for Macintosh OS-X, The University of Tokyo 
Hospital), while Ce was numerically calculated using the Newton-Raphson method. In 
monkeys and humans, the fitting was performed for intravenous bolus data. 
 
RESULTS 
Pharmacokinetics of HGF in normal and ARF mice 
HGF was intravenously administered in mice at three different doses as a bolus 
(Fig. 1a) or infusion (Fig. 1b). The doses of the bolus injection were based on the amount of 
HGF which exhibited pharmacological effect in the previous reports (0.3 - 1 mg/kg; 3,29). 
The infusion study was performed in addition to the bolus injection study with an aim to 
increase the plasma concentration data especially at lower range and support the goodness 
of the fitting in the pharmacokinetic modeling. This infusion was performed only for 30 
min to minimize the externalization and subsequent recovery of HGF receptor during the 
infusion period. Disappearance of HGF after the single bolus dose was initially quite rapid, 
followed by a slower phase of disappearance in rodents (Fig. 1a). After the start of the 
infusion, the plasma HGF concentration rapidly increased and approached a plateau value 
(Fig. 1b).  
Clinical development of HGF is now ongoing for treatment of ARF ahead of 
other diseases. Therefore, we next examined the effect of ARF on the pharmacokinetics of 
HGF with an aim to construct pharmacokinetic model in the ARF condition. Glycerol was 
intramuscularly injected in mice to construct the ARF model (Fig. 2a). At 24 hr after single 
injection of glycerol, both BUN and ALT in plasma was higher than those in the 
saline-treated group, whereas only BUN was significantly higher than the control at 48 hr 
(Fig. 2b, 2c), suggesting that the glycerol injection resulted in injury to both liver and 
kidney at 24 hr, but the hepatic function had recovered by 48 hr. Therefore, mice at 48 hr 
after the glycerol injection were used as the ARF model, and the plasma concentration 
profile of HGF after intravenous injection was examined. The plasma concentration in the 
ARF model could be almost superimposed on that in control mice (Fig. 2a), suggesting a 
minimal effect of ARF on systemic clearance of HGF. Moreover, AUC/Dose and T1/2 in 
ARF mice were similar to those in normal mice (Table 1). Therefore, we did not further 
consider the pharmacokinetic modeling of HGF in the ARF condition. 
To examine the local events that may influence the pharmacokinetics of HGF, 
FITC-HGF was intravenously injected into normal and ARF mice, and fluorescence images 
were taken of frozen sections from kidney and liver (Fig. 3). In our preliminary study, a 
nonspecific signal was observed throughout the sections of both organs, probably because 
of efficient binding of HGF to cell-surface heparin-like substance. Therefore, heparin was 
also injected to remove such binding before the detection of fluorescence. FITC-HGF was 
detected in renal tubular epithelial cells in both normal and ARF mice (Fig. 3a, 3b, 3d, 3e). 
Compared with the normal kidney (Fig. 3a), the kidney sections from ARF mice more 
obviously showed tubular dilatation which was regarded as the damaged tubules according 
to the previous reports. 30 In kidney of ARF mice, fluorescence was clearly seen in those 
damaged tubules (Fig. 3d, 3e). Fluorescence was detected in vesicular structures of kidney 
in both normal and ARF mice (Fig. 3b, 3e), and further, the fluorescence inside hepatocytes 
was similar in normal and ARF mice (Fig. 3c, 3f). To confirm the specific endocytosis of 
FITC-HGF via the HGF receptor, FITC-HGF with or without unlabeled HGF (30 mg/kg) 
was intravenously administered, and fluorescence in the kidney section was observed (Fig. 
3g, 3h). The fluorescence was much reduced by the unlabeled HGF (Fig. 3g, 3h), 
suggesting receptor-mediated endocytosis of FITC-HGF. Additionally, to confirm 
localization of intact human HGF in the kidney, immunostaining using antibody for human 
HGF was performed in the kidney sections prepared from the mice administered with 
FITC-HGF. The immunostaining signal was detected in the kidney section, but reduced 
when the antibody was absorbed by its antigen (Fig. S2 in Supporting Information), 
suggesting that at least a part of FITC-HGF localized in the kidney was intact. To further 
support the damage of renal tubules in the ARF mice, we examined pharmacokinetics of 
cephalexin, which is known to be highly secreted in renal tubules. Plasma clearance of 
cephalexin assessed in different mice in the same ARF condition was much reduced (22% 
of that in control mice). 
 
Model-independent and compartment analyses  
Pharmacokinetic parameters in mice obtained by model-independent analysis of 
plasma concentration profiles were shown in Table 1. Steady-state distribution volume 
(Vdss), mean residence time (MRT) and half-life at terminal phase (T1/2) increased as the 
increase in Dose (Table 1), indicating that elimination of HGF is delayed possibly because 
of saturation of elimination mechanism. On the other hand, the dose-normalized AUC 
(AUC/Dose) and total clearance (CLtot) were similar among all doses (Table 1). Plasma 
concentration profile at early phase (~60 min) was almost parallel at three doses (Fig. 1a, 
inset). In addition, the dose normalized AUC at the early phase (AUC0-60/Dose) showed 
minimal difference among all doses and accounted for the major portion of total AUC 
(AUC0-60/AUC0-inf > 74% for all the doses, Table 1). Thus, pharmacokinetics of HGF at the 
initial phase was almost linear, but that at terminal phase was nonlinear, suggesting the 
complex pharmacokinetic behavior of HGF.  
 Plasma concentration profile in mice after bolus injections (Fig. 1a) were next 
simultaneously fitted to the compartment models. The analysis using two-compartment 
model provided the best goodness of fit, Akaike’s information criterion being the lowest 
than the other compartment models. Nevertheless, the fitting cannot fully explain overall 
plasma concentration profiles even after the single dose (Fig. 1a).  
 It should be noted that trough concentration was increased by the repeated doses 
(Fig. 4c, 4d, 4e, 4f), and this cannot be simply explained by the compartment model. HGF 
is known to be eliminated via at least two types of specific receptor.15-18 Therefore, we next 
attempted to construct mechanism-based pharmacokinetic model including 
receptor-mediated endocytosis (Fig. S1) with an aim to understand pharmacokinetic 
mechanism. 
 
Pharmacokinetic modeling of HGF in experimental animals and humans 
First, plasma concentration profiles after bolus injection and during infusion in 
mice (Fig. 1) were simultaneously fitted to the model shown in Fig. S1. To minimize the 
number of parameters to be estimated in the fitting, the Kd values for c-Met and 
heparin-like substance were fixed at the reported values26,27. In addition, Vsyn could not be 
determined by the fitting of single-dose data and therefore was fixed to be zero. Therefore, 
the parameters estimated by the fitting were Vp, Ve, Rss,1, kint,1, Rss,2 and kint,2. The results 
are listed in Table 2. The pharmacokinetic model reasonably well described the plasma 
concentration profiles in mice after bolus injection and during infusion (Fig. 1). 
A similar fitting procedure was also performed for reported pharmacokinetic 
data18,19 obtained in rats. The plasma concentration profiles after bolus injection and during 
infusion in rats were simultaneously fitted to the model, and the fitted lines coincided well 
with the data (Fig. 4a, 4b). The kint values estimated by the fitting in rats (0.074 - 0.177 
min-1, Table 2) were higher than those in mice, but not very different from the reported 
value (~ 0.1 min-1) for the internalization of HGF observed in perfused rat liver.31 
In monkeys, preclinical data had been previously obtained after repeated 
intravenous injection of HGF at three different doses for 28 days (Fig. 4c, 4d, 4e, 4f). A 
similar fitting procedure to that used in the case of rodents was first performed for the data 
at day 1 (Fig. 4c), but the fitting was unsuccessful when the two Kd values were fixed, 
probably because the concentration range of HGF in monkeys appeared to be higher than in 
the other animals, and few plasma concentration data were available in to the region of the 
reported Kd value for c-Met (2.62 ng/mL) in monkeys (Fig. 4c), leading to difficulty in 
estimation of kinetic parameters associated with c-Met (Rtot,2, Kd,2 and kint,2) by fitting. 
Therefore, we fixed the values of these three parameters to be the same as those in rats, and 
then performed the fitting of the data at day 1 in monkeys. The fitting was successful when 
CLns was included in addition to c-Met and heparin-like substance. Vsyn,HGF was next 
estimated and fixed to yield an endogenous HGF concentration of 0.478 ng/mL, which was 
the mean value of plasma endogenous HGF obtained before the HGF injection in monkeys 
in the preclinical studies. Then, simultaneous fitting of all the data on days 1, 3, 14 and 28 
at the three doses to the model was performed to estimate Rss,2, Kd,2, CLns, Vsyn,1 and V syn,2, 
and this yielded the parameter values shown in Table 2. Here, the kdeg was assumed to be 
equal to Vsyn/Rss according to Eq. (5) and not directly estimated by the fitting. Thus, the 
pharmacokinetic model can describe the plasma concentration profile after repeated 
injections at all the doses examined (Figs. 4c, 4d, 4e). It should be noted that Kd,2 in 
monkey was estimated to be much higher than the reported Kd value27 for the association of 
HGF with c-Met (Table 2).  
The fitting procedure in humans was performed using the reported 
pharmacokinetic data after intravenous single administration24. In humans, the parameters 
for c-Met (Rss,2, Kd,2 and kint,2) could not be estimated because data at only one dose are 
available in the literature24 (Fig. 4g). Therefore, the parameters for c-Met and Kd,1 were 
fixed at the same values as those in monkeys to estimate Vp, Ve, Rtot,1 and kint,1 by fitting 
(Table 2). Since only pharmacokinetic data after single administration were reported in 
humans, the fitting did not include CLns or Vsyn,HGF. The fitted line coincided well with the 
data (Fig. 4g). 
Overall, the Vp estimated by this fitting in rats and humans was close to the 
plasma volume (30~50 mL/kg)25 and the reported value (52 mL/kg) obtained in rats,16 but 
the values in mice and monkeys were higher (Table 2). The Ve in all species was much 
higher than the extracellular volume (10~20 mL/kg)25 in the liver (Table 2). 
DISCUSSION 
HGF exhibits various pharmacological activities in experimental renal failure 
models and is currently under development as a therapeutic agent for kidney injury. 
However, there has been no information on its pharmacokinetics in renal failure. Therefore, 
we first compared the pharmacokinetics of HGF between normal and ARF mice. We found 
that the plasma concentration profile after intravenous injection was similar in the two 
groups (Fig. 2a), indicating that only a minimal change in systemic clearance of HGF 
occurs during renal failure. Intrahepatic distribution of FITC-HGF also exhibited only a 
minimal difference between the groups (Fig. 3c, 3f). Several pharmacokinetic studies in 
rats have indicated that liver is the major clearance organ for HGF.16-19 Therefore, the 
minimal change in pharmacokinetics in the ARF model (Fig. 2a, Table 1) can be explained 
by the minor contribution of the kidney to systemic clearance. It is noteworthy, however, 
that renal handling of FITC-HGF exhibited some difference between normal mice and the 
ARF model: FITC-HGF was evenly distributed to renal tubules in control mice (Fig. 3a, 
3b), whereas it was highly distributed to and internalized in damaged tubules in the ARF 
model (Fig. 3d, 3e). This may be compatible with the potent biological activities of HGF in 
renal tubules, such as anti-fibrosis, anti-apoptosis and stimulation of tubular 
proliferation.3-5,7,32,33 In addition, the HGF distribution specifically to damaged tubules may 
be governed by similar mechanisms to those involved in proliferative activity of HGF and 
down-regulation of c-Met/HGF receptor in regenerating organs in vivo.34,35 Thus, HGF 
appears to be efficiently endocytosed in injured renal tubules, but such renal handling only 
minimally affects its overall clearance. HGF should be difficult to be filtered through 
glomerulus because of its large molecular size (> 80 kDa). Therefore, endocytosis of HGF 
should occur from basolateral membranes in normal kidney. However, structure of 
glomerulus could be damaged in ARF mice because of the increase in BUN (Fig. 2b). In 
addition, c-Met was reported to be localized on both basolateral and apical membranes.36 
Therefore, a part of HGF may be filtered and endocytosed from apical membranes in ARF 
condition. 
Receptor-mediated endocytosis plays an important role in systemic clearance of 
various types of therapeutic proteins.37-39 In addition, target-mediated disposition has been 
proposed for various types of therapeutic proteins and monoclonal antibodies.40,41 In both 
cases, however, a single type of receptor/target is generally considered to be involved in 
systemic clearance. On the other hand, clearance of HGF has been suggested to be 
mediated by at least two binding sites, c-Met and cell-surface heparin-like substance.16-18,31 
Most of the data supporting the involvement of the two clearance sites were, however, 
obtained using systemically administered 125I-labeled HGF as a tracer.15-17,31 Thus, it has 
remained unclear whether the two sites are involved in HGF clearance over the same range 
of HGF concentrations. In the present study, our pharmacokinetic model assuming at least 
two binding sites in the liver could very well explain the plasma concentration profiles 
observed at various doses in mice, rats, monkeys and humans (Figs. 1, 4). Fitting was 
successful at all the doses examined in the case of both bolus and infusion studies in 
rodents, and repeated doses in monkeys (Figs. 1, 4). These results suggest that systemic 
elimination of HGF is mediated by at least two clearance sites in the liver over a wide range 
of doses in various dose regimens. Nevertheless, pharmacokinetic information in humans is 
still quite limited, and therefore, kinetic parameters for only the low-affinity site were 
estimated by fitting of the plasma concentration profile (Fig. 4g). The difference in 
pharmacokinetics between human and mice may result from that in the affinity of human 
HGF to mouse and human c-Met. Nevertheless, the data in humans (Fig. 4g) include only 
plasma concentrations higher than 10 ng/mL, which would be enough to saturate the 
binding of HGF to c-Met, if we consider the dissociation constant of the interaction (~2.62 
ng/mL).27 This may bias the estimation of exact value for the affinity to c-Met in humans. 
Therefore, pharmacokinetic modeling in humans will need to be re-evaluated when further 
information becomes available at various doses. In addition, the Kd,2 in monkeys was much 
higher than the reported Kd value27 for the association of HGF with c-Met (Table 2). 
Non-saturable elimination clearance (CLns) was obtained only in monkeys (Table 2). 
Although reasons for these phenomena remain to be established, it is noteworthy that the 
data in monkeys were obtained in a 28-day toxicity study, which included relatively high 
doses. In monkeys, the number of plasma concentration data close to the Kd value for 
c-Met (2.46 ng/mL) was quite limited; most of the data were obtained within the range of 
102~105 ng/mL (Figs. 4c-4f). Therefore, the parameters obtained by the fitting in monkeys 
may mainly represent those in a higher dose range than the clinically relevant one. 
 The terminal phase after bolus injection exhibited nonlinear behavior in mice, the 
half-life and MRT being prolonged at higher doses (Fig. 1a, Table 1). This was also the case 
in rats and monkeys (Fig. 4) and can be explained by a nonlinear elimination mechanism 
such as RME. In addition, such a prolonged half-life at higher doses was observed even for 
the same plasma concentration range: for example, in the plasma concentration range of 
10-100 ng/mL, the elimination curve was more gradual at 21.7 mg/kg compared with those 
at 0.72 and 2.33 mg/kg in mice (Fig. 1a). A similar phenomenon was found in rats and 
monkeys (Fig. 4). In addition, at higher plasma concentration of HGF (104~105 ng/mL), the 
elimination at the highest dose was slightly slower than that at lower doses (Fig. 1a, inset). 
These results cannot be simply explained by nonlinear elimination and may indicate 
exposure-dependent elimination kinetics. Such unique kinetics may be inconsistent with the 
application of a simple Michaelis-Menten type kinetic model to the disposition of HGF. 
The pharmacokinetic model proposed in the present study includes endocytosis of 
HGF-receptor complex at both high- and low-affinity sites. Therefore, higher exposure of 
HGF to c-Met and/or heparin-like substance leads to a decrease in receptor density 
(down-regulation) on the cell surface, resulting in a delay of systemic elimination. The 
fitted lines obtained for the data after single bolus administration fairly well explain such 
elimination profiles in all the animals (Figs 1, 4), supporting the validity of the RME model 
proposed in the present study. 
 The model-independent analysis revealed unique characteristics in 
pharmacokinetics of HGF (Table 1). Vdss, MRT and T1/2 were dose-dependent whereas 
AUC/Dose and CLtot were dose-independent (Table 1). When we observed details in 
plasma concentration profile (Fig. 1a), nonlinear behavior was observed primarily at the 
terminal phase: The elimination curve at the terminal phase was more gradual at the higher 
doses (Fig. 1a), leading to the prolonged T1/2 and MRT, and larger Vdss (Table 1). On the 
other hand, plasma concentration profile at the initial phase showed minimal nonlinear 
behavior. Actually, the AUC0-60/Dose was almost close among all the doses and accounted 
for a large part of AUC until infinite time (Table 1). Thus, even when other parameters like 
Vdss, MRT and T1/2 exhibited dose-dependence, AUC/Dose and CLtot were apparently 
dose-independent probably because they were largely affected by the plasma profile at the 
initial phase. The mechanism for nonlinear behavior especially at the terminal phase was 
still unknown, but can be accounted for by the down-regulation of HGF receptors due to the 
long-time exposure to HGF according to the present pharmacokinetic model. 
 HGF receptor density on the cell surface gradually recovers after endocytosis 
induced by HGF. Indeed, Liu et al.15 kinetically analyzed the recovery of c-Met in rats in 
vivo and obtained a half-life of 1~3 h for the recovery in various organs. The 
pharmacokinetic model in the present study includes the recruitment of both c-Met and 
heparin-like substance to the cell surface. Nevertheless, the pharmacokinetic profile after 
single intravenous bolus administration and during short-term (30~90 min) infusion could 
be explained even when Vsyn was set to be zero (see Results), suggesting that recovery of 
the HGF receptors may only minimally affect pharmacokinetics of HGF after a single dose. 
On the other hand, repeated injection of HGF in monkeys caused a gradual increase in 
trough values (plasma HGF concentration at 1,440 min in Fig. 4c-4f). The increase in the 
trough values was marked at higher dose (30 mg/kg), but was also apparent at the lowest 
dose (0.3 mg/kg, Fig. 4c-4f). There are at least two possible explanations for such a 
phenomenon. One is the induction of biosynthesis of HGF in the body, and the other is a 
decrease in recruitment of HGF receptors after repeated injections. The injection of HGF 
and plasmid encoding HGF gene are known to induce biosynthesis of HGF in vivo,3,42 
supporting the former possibility. However, the enzyme immunoassay used in the monkey 
studies cannot distinguish endogenous (monkey) HGF from human HGF exogenously 
administered, and therefore, we cannot identify the contribution of endogenous HGF to the 
increase in the trough values. The trough concentration of HGF at the highest dose (30 
mg/kg) was 102~104 ng/mL (Figs. 4c-4f). These values are very much (103~105 times) 
higher than the endogenous plasma concentration. On the other hand, Mizuno et al.3 
reported that HGF supplement induced an increase in the endogenous HGF level in kidney 
in mice, but the increase was less than two-fold versus the saline control. Ueki et al.42 
reported an increase in endogenous HGF level in circulating plasma after transduction with 
the HGF gene, but the increase was at most four-fold versus the control. Thus, it seems 
unlikely that induction of biosynthesis of endogenous HGF can fully explain the increase in 
the trough values. On the other hand, Hammond et al. reported that HGF induced 
degradation of c-Met, leading to a decrease in the protein level.28 This supports the latter 
possibility, i.e., a gradual decrease in recruitment of HGF receptors to the cell surface 
during exposure to HGF. Such a decrease in recruitment of HGF receptors to the cell 
surface causes another type of down-regulation (a decrease in receptor density), which is 
different from that induced simply by endocytosis of HGF-receptor complex. We 
incorporated such a decrease in recruitment of HGF receptors during repeated doses of 
HGF into our model, and this assumption could at least partially explain the increase in the 
trough concentration (Fig. 4c-4f). Thus, recruitment of HGF receptors may affect the 
pharmacokinetics after repeated doses, although further studies are needed to clarify the 
precise mechanism(s) involved. 
 After intravenous bolus injections, HGF initially disappears with a quite short 
half-life in plasma (~ 4 min).16 This was also observed in the present study in animals and 
human (Figs. 1, 4). The rapid elimination was apparent within a short period after injection 
(~15 min), and there was a more than two-order-of-magnitude decrease in plasma HGF 
concentration, followed by a slower elimination phase (Figs. 1, 4). Such a rapid and 
transient decrease at the initial phase after intravenous bolus injection can be explained by 
the rapid association of HGF with cell-surface binding sites. Actually, after intravenous 
administration of 125I-HGF, tissue uptake clearance of the isotope at the initial phase (1~ 5 
min) was much higher in the liver, compared with other organs.16 Therefore, in the present 
study, we assumed the presence of two cell-surface receptors in the liver compartment (Fig. 
S1). Nevertheless, the fitting procedure yielded Ve values much higher than the 
physiological values (Table 2), indicating rapid association of HGF with other binding sites 
in the extracellular space. Various types of binding sites have been proposed for HGF. For 
example, HGF binds not only to heparan-sulfate proteoglycans,43 but also to various other 
types of glycosaminoglycans, such as dermatan sulfate.26 c-Met is expressed not only in 
hepatocytes, but also in endothelial cells.44 Further work will be needed to clarify the 
molecular mechanisms involved in such extremely high Ve. 
Distribution of FITC-HGF into the kidney in ARF seems to be different from that 
in normal condition (Fig. 3a, 3d) whereas the pharmacokinetic model did not include the 
kidney (Fig. S1). This was because the pharmacokinetic model constructed in the present 
study was aimed to simply describe the systemic concentration of HGF. The liver is the 
major clearance organ for HGF16-19, and HGF is largely distributed to the liver compared 
with other organs including kidney. 16,45,46 Kato et al19 directly estimated renal clearance of 
HGF and found its minimal contribution to systemic clearance in rats. The minimal 
contribution of the kidney to systemic clearance could be compatible with the present 
finding that plasma concentration profile in ARF mice was similar to that in normal mice 
(Fig. 2a). Thus, the pharmacokinetic model did not include the kidney compartment (Fig. 
S1). Nevertheless, we still have to consider the possible relevance of the renal handling of 
HGF to its potential biological activity in renal tubules. Thus, the distribution kinetics of 
HGF in the kidney may have to be considered to construct pharmacodynamics model which 
should be constructed by further analyses. 
In conclusion, ARF may not affect systemic clearance of HGF, though 
internalization of HGF occurs efficiently in damaged renal epithelial cells. Two clearance 
mechanisms can principally account for the pharmacokinetic profiles of HGF in various 
dose ranges. Recruitment of HGF receptors minimally affects the pharmacokinetics of HGF 
after single dosing, but could account for the increase in trough values after repeated dosing. 
The pharmacokinetic model proposed in the present study is expected to contribute to the 
safe and efficient management of further clinical studies for the development of HGF as a 
therapeutic agent. 
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LEGENDS TO FIGURES 
Fig. 1  Plasma concentration profile of HGF and fitted curves obtained with the 
pharmacokinetic model after intravenous bolus injection and during intravenous 
infusion in mice 
HGF was injected at a dose of 0.72 (△), 2.33 (◇) or 21.7 (○) mg/kg as a bolus 
in (a) and infused at a dose of 100, 300 or 1,200 ng/min/kg in (b). Plasma concentration 
was determined by enzyme immunoassay. Data within a short time period are also shown in 
the inset. Data represent mean ± SEM (n =3 - 4). Dotted lines represent fitted curves 
derived from two-compartment analysis. Straight liLines represent fitted curves derived 
from the pharmacokinetic model.  
 
Fig. 2  Effect of ARF on pharmacokinetics of HGF in mice 
The ARF model was constructed in mice by intramuscular injection of glycerol. 
Saline was intramuscularly injected as a control. HGF was intravenously injected at a dose 
of 2.33 mg/kg at 48 hr after the glycerol injection. Panel (a) Plasma concentration, 
determined by enzyme immunoassay, in normal (◇) and ARF (◆) mice. Panel (b) BUN 
level in plasma, determined at 24 hr after glycerol injection in normal (open bars) and ARF 
(closed bars) mice. Panel (c) ALT level in plasma, determined at 48 hr after glycerol 
injection in normal (open bars) and ARF (closed bars) mice. Data represent mean ± SEM (n 
=7 - 12).  
*, Significantly different from saline-treated group (p < 0.05) 
 
Fig. 3  FITC-HGF was internalized into renal tubular cells in normal and ARF mice 
Fluorescence was detected using confocal microscopy in frozen tissue sections 
obtained from kidney (a, b, d, e) and liver (c, f) at 15 min after intravenous injection of 
FITC-HGF (2.01 mg/kg) in normal (a, b, c) and ARF model (d, e, f) mice. In panels (g) and 
(h), FITC-HGF with (h) or without (g) unlabeled HGF (30 mg/kg) was administered, and 
fluorescence was detected using confocal microscopy on the same gain setting for 
comparison between each panel. Note that fluorescence was detected in damaged tubular 
structures showing tubular dilatation (arrowheads) in panels (d, e). 
 
Fig. 4  Plasma concentration profiles of HGF and fitted curves obtained with the 
pharmacokinetic model in rats, monkeys and humans 
Plasma concentration in rats after intravenous bolus injection (panel a) at 0.1 (×), 
0.3 (—), 1 (＊), 3 (□), 10 (■), or 30 (△), 120 (▲), 300 (◇), 500 (◆), 710 (○) or 1,000 
(●) µg/kg and during intravenous infusion (b) at 0.0133 (△), 0.0310 (▲), 0.0703 (◇), 
0.230 (◆), 1.07 (○), or 5.77 (●) µg/min/kg were taken from the literature.18,19 Data 
within a short time period are also shown in the inset of panel (a). Plasma concentration in 
monkeys after repeated intravenous injection (once per daily) at 0.3 (△), 3 (◇) or 30 (○) 
mg/kg at day 1 (c), day 3 (d), day 14 (e) and day 28 (f) was taken from an unpublished 
preclinical study (Kringle Pharma Inc.). Note that the trough values (at 1,440 min in each 
panel) gradually increased during repeated dosing. The value of 1.43 mg/kg in humans with 
chronic liver disease (g) was taken from the literature.23 Lines represent fitted curves 
derived from the pharmacokinetic model.  
 
